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Adenosine A2A receptor mediates the promotion of wound healing and revascularization of
injured tissue, in healthy and animals with impaired wound healing, through a mechanism
depending upon tissue plasminogen activator (tPA), a component of the fibrinolytic
system. In order to evaluate the contribution of plasmin generation in the
proangiogenic effect of adenosine A2A receptor activation, we determined the
expression and secretion of t-PA, urokinase plasminogen activator (uPA), plasminogen
activator inhibitor-1 (PAI-1) and annexin A2 by human dermal microvascular endothelial
cells stimulated by the selective agonist CGS-21680. The plasmin generation was assayed
through an enzymatic assay and the proangiogenic effect was studied using an endothelial
tube formation assay in Matrigel. Adenosine A2A receptor activation in endothelial cells
diminished the release of PAI-1 and promoted the production of annexin A2, which acts as
a cell membrane co-receptor for plasminogen and its activator tPA. Annexin A2 mediated
the increased cell membrane-associated plasmin generation in adenosine A2A receptor
agonist treated human dermal microvascular endothelial cells and is required for tube
formation in an in vitro model of angiogenesis. These results suggest a novel mechanism
by which adenosine A2A receptor activation promotes angiogenesis: increased endothelial
expression of annexin A2, which, in turn, promotes fibrinolysis by binding tPA and
plasminogen to the cell surface.
Keywords: annexin A2, microvascular endothelial cells, plasminogen activator inhibitor-1, tissue plasminogen
activator, urokinase plasminogen activator, adenosine receptors
INTRODUCTION
Adenosine is a ubiquitous nucleoside that participates actively in regulating different physiological
processes involved in tissue repair and wound healing, inflammatory and immune responses, or
formation of new blood vessels (Valls et al., 2009; Borea et al., 2018). Among the four distinct
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its effects, A2A receptor activation has been reported to promote
wound healing (Shaikh and Cronstein, 2016; Colangelo et al.,
2020; Troncoso et al., 2020). The contribution of adenosine A2A
receptor in wound healing has been further confirmed in A2A-
deficient mice, characterized by reduced blood vessel network and
delayed granulation tissue formation (Montesinos et al., 2002).
Furthermore, the adenosine A2A receptor agonist CGS-21680
stimulates both vasculogenesis and angiogenesis at an early stage
(<3 days) of wound repair (Montesinos et al., 2004).
Plasminogen and its active form plasmin belong to an
enzymatic system involved in intravascular and extravascular
fibrinolysis, as well as in tissue repair and remodeling by
regulating extracellular matrix degradation, cell migration,
tissue formation, angiogenesis, and embryogenesis (Rubina
et al., 2017; Plekhanova et al., 2019). The activity of this
system is self-regulated by several factors such as tissue-type
plasminogen activator (t-PA), urokinase-type plasminogen
activator (u-PA) or the plasminogen activator principal
inhibitor PAI-1 (Simone et al., 2015). In addition, there are
other molecules that interact with the fore mentioned
plasminogen factors resulting in the modulation of their
activity. Annexin A2 is a member of a family of calcium-
dependent membrane-binding proteins that acts as co-receptor
for plasminogen and t-PA (Liu and Hajjar, 2016; Mirsaeidi et al.,
2016). Consequently, annexin A2 deficient mice present
deficiencies in plasmin generation through a mechanism
dependent on t-PA (Ling et al., 2004).
Our previous results confirm that adenosine A2A receptor
activation promotes wound closure by a mechanism that depends
on t-PA, but not on u-PA expression (Montesinos et al., 2015).
We also found that increased revascularization of the wound bed
upon treatment with agonists of adenosine A2A receptors occurs
via a mechanism dependent on t-PA (Montesinos et al., 2015). In
this study, we sought to provide insight into the pharmacological
promotion of angiogenesis by an adenosine receptor agonist
through a mechanism dependent upon plasminogen activation.
We showed that adenosine A2A receptor activation diminishes
PAI-1 production and promotes tubular network formation in
human dermal microvascular endothelial cells (HDMVEC). This
proangiogenic effect observed upon adenosine A2A receptor




The adenosine 2A receptor agonist CGS-21680 (2-p-[2-
carboxyethyl] phenethyl-amino-5′-N-ethylcarboxamido-adenosine)
was obtained from Tocris bioscience (Cat #1063). Polyclonal goat
antibodies against tPA (Cat #387), uPA (Cat #398) and PAI-1 (Cat
395G) were obtained from American Diagnostica inc.; monoclonal
mouse antibody against annexin A2 from BD Transduction
Laboratories (Cat #610069); rabbit antibody against ß-actin from
SigmaChemical Co. (Cat #A2066); Alexa fluor® 488 goat anti-mouse
(Cat #A1101) antibody from Molecular Probes Ltd. All other
materials were the highest quality that could be obtained.
Cell Culture
Human dermal microvascular endothelial cells (HDMVEC) from
neonate foreskin (Lonza, Cat #CC-2505) were cultured up to
80–90% confluence in supplemented EGM-2MV medium
(Lonza, Cat #CC-3202) at 37°C and 5% CO2 in a humidified
atmosphere. Cells used in all experiments were between passages
5 and 7. The night prior the experiments, mediumwas replaced to
0.1% Bovine Serum Albumin (BSA, ELISA grade, Sigma
Chemical Co., Cat #A7030) supplemented EBM-2 medium
(Lonza, Cat #CC-3156). All experiments were carried out in
0.1% BSA basal medium.
ELISA
HDMVEC, cultured in 24 well plates, were incubated in the
absence (control) or presence of increasing concentrations
(10−7–10–5 M) of the selective A2A adenosine receptor agonist
CGS-21680 in 0.1% BSA basal medium for 24 h at 37 °C and 5%
CO2. Supernatants were collected and frozen at -80 °C until ELISA
determination. Cell viability was determined by cellular reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, 0.2 mg/ml, Sigma Chemical Co. Cat #M2003) to
formazan, solubilization in DMSO and absorbance measurement
at 490 nm. Concentration of total tPA, uPA and PAI-1 antigens
present in conditioned media were determined using commercially
available assays: IMUBIND® tPA (Cat #860), uPA (Cat #894) or
PAI-1 (Cat #822) ELISA (American Diagnostica Inc.). Sensitivity
of the kit for tPA is 0.2 ng/ml, for uPA is 0.02 ng/ml and for
PAI-1 is 1 ng/ml. Results were normalized to 105 viable cells
per well.
Real Time RT-PCR
Total RNA (1 µg) isolated from cultured cells using Trizol reagent
(Invitrogen Cat# 15596018) was transcribed into cDNA (RT)
using the RNA PCR Core Kit (Applied Biosystems™ N8080143).
Aliquots of RT were subjected to real-time PCR using the
Mx3005P system (Stratagene, La Jolla, CA), SYBR-Green
Brilliant Master Mix (Stratagene Cat #600548) and specific
primers for t-PA (Forward 5′-CCCAGATCGAGACTCAAA
GC-3′ Reverse 5′-TGGGGTTCTGTGCTGTGTAA-3′, NCBI
Reference Sequences: NM_000921 and NM_033011), u-PA
(Forward 5′-ATTCACCACCATCGAGAACC-3′ Reverse 5′-
TCCACCTCAAACTTCATCTCC-3′, NCBI Reference
Sequence: NM_002658), PAI-1 (Forward 5′-CTGGTTCTG
CCCAAGTTCTC–3′ Reverse 5′-GACTGTTCCTGTGGGGTT
GT-3′, NCBI Reference Sequence: NM_000602), and GAPDH
(Forward 5′-AACATCATCCCTGCCTCTAC–3′ Reverse 5′-
CCCTGTTGCTGTAGCCAAAT-3′); Annealing Temperature:
60°C. All values were normalized to GAPDH as described
(Che et al., 2007). All primers were designed in a way that the
PCR products spanned an intron.
Cell Immunofluorescence Microscopy
HDMVEC were grown on chamber slides (Nalge Nunc
International, Cat #177402). After treatment, medium was
discarded, and cells were fixed in ice cold 70% ethanol and
blocked with 2% BSA in 0.01% (vol/vol) Tween 20 PBS -
(PBST). Slides were incubated with primary antibodies against
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proteins of interest and subsequently incubated with Alexa Fluor
488 secondary antibodies, nuclei were counterstained with
Hoerschst 33342 (Molecular Probes Inc. Cat #H21492) and
slides were mounted in fluorescence mounting medium
(DakoCytomaton, Glostrup, Denmark). Negative controls
were run in parallel without the primary antibody.
Fluorescence was detected with a Nikon Eclipse e800
microscope coupled with an automated imager Nikon ACT-1
(Nikon Instruments Inc. Melville, NY) and fluorescence
intensity was blindly quantified with MetaMorph software
(Molecular Devices Corporation, Downington, PA) by an
independent observer.
Confocal Laser Scanning Microscopy
HDMVEC were seeded on poly-L-lysine (100 μg/ml) coated
24 mm diameter glass coverslips in six-well plates. After
treatment, calcium-dependent translocation of annexin A2 to
the membrane (Monastyrskaya et al., 2007) was induced by
addition of 10−6 M ionophore A23187 (Sigma Chemical Co.,
Cat #C7522) for 5min. Then, medium was discarded and cells
were fixed in ice cold 70% ethanol, blocked with 2% BSA in 0.01%
(vol/vol) Tween 20 PBS - (PBST), incubated with primary
antibodies against annexin A2, subsequently incubated with
Alexa Fluor 488 goat anti-mouse antibody and nuclei were
counterstained with Hoerschst 33342. Confocal images were
obtained on a LEICA TCS SP2 (DM-IRB) laser-scanning
microscope. A z-series of images were acquired at 2 µm steps
to produce individual z-stacks. The resulting images were
overlaid and analyzed using the Leica software, v2.61 (Leica
Geosystems AG, Heerbrugg, Suiza).
Western Blot Analysis
HMVEC, cultured in 6 well plates, were incubated in the absence
(control) or presence of the selective A2A adenosine receptor
agonist CGS-21680 in 0.1% BSA basal medium for 24 h at 37°C
and 5% CO2. Supernatants were removed and cells were rinsed in
ice-cold phosphate-buffered saline (PBS), pH 7.4 and lyzed at 4°C
in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% SDS, 1%
Nonidet P-40 and 0.5% sodium deoxycolate) plus protease
inhibitors (leupeptin, aprotinin and PMSF). Following
centrifugation (10000g, 10 min) equal amounts of protein (5
or 25 µg/lane) were separated by 10% SDS-PAGE under
reducing conditions and electrophoretically transferred onto
poly-(vinylidene difluoride) (PVDF) membranes, blocked with
3% nonfat milk in 0.1% (vol/vol) Tween 20 phosphate
buffered saline (PBST) and then incubated with specific
antibodies against the protein of interest. After extensive
washes, blots were incubated with a horseradish
peroxidase-conjugated secondary antibody and the
immunoreactive bands were visualized by enhanced
chemiluminescence (Amersham Biosciences, Cat
#RPN2232) using the AutoChemi image analyzer and
Labworks 4.6 software (UVP, Inc. Upland, CA).
Co-Immunoprecipitation
After treatment, HDMVEC cultured in T25 flasks were lyzed with
1 ml of lysis buffer (50 mMTris pH 7.4, 150 mMNaCl, 0.1% SDS,
1% Nonidet P-40 and 0.5% sodium deoxycolate) containing
protease inhibitors (leupeptin, aprotinin and PMSF). Whole
cell lysates were precleared for 30 min at 4°C with 0.25 µg of
appropriate control (normal) IgG, corresponding to the host
species of the primary antibody (Mouse IgG, Sigma Chemical
Co., Cat #I5381), and 20 µL of protein A/G-agarose (Santa Cruz
Biotechnology, Inc. Cat #sc-2003). The precleared cell lysates
were subsequently incubated with 2 µg of the monoclonal
antibody against annexin A2 for 2 h at 4°C before the addition
of 20 µL of protein A/G-agarose, and the incubation was
continued overnight at 4°C with constant rotation. Next, the
agarose beads were pelleted by centrifugation at 2500 rpm
(1,000g) for 5 min at 4°C. After extensive washes with ice-cold
lysis buffer, beads were resuspended in sample loading buffer,
boiled for 4–5 min, and subject to Western blotting with specific
antibody against tPA.
Plasmin Generation Test
Plasminogen activation was determined as the ability of
generated plasmin to degrade a specific fluorogenic substrate
by membrane bound exogenous tPA (Diaz et al., 2004).
HDMVEC (104 cells/well) were cultured in 96 well
microplate, black, clear bottom (Corning Incorporated, Cat
#CLS3603). After treatment, supernatants were removed, and
cells were washed twice with PBS and incubated with 10 nM of
single-chain recombinant tPA (American Diagnostica inc. Cat
#173) in PBS-BSA 2% for 30 min. After washing three times
with PBS to remove unbound tPA, 100 nM Glu-plasminogen
(Calbiochem, manufactured by EMD Biosciencies, Inc.; Cat
#528180) and 50 µM of the fluorogenic substrate D-Ala-Leu-
Lys-7-amido-4-methylcoumarin (Sigma Chemical Co., Cat
#A8171) in buffer 0.05 M Tris-HCl, 0.1 M NaCl, 0.01%
Tween 20, pH 7,4 were added. Plasmin formation was
monitored at 360-nm excitation/460-nm emission setting in a
spectrofluorimeter plate reader (Perkin-Elmer WALLAC
Victor2 1420, Perkin-Elmer life sciencies, Turku, Finland) at
5- or 30-min intervals for 6 h at 37°C. The basal fluorescence
obtained at 0 min was subtracted from each time point.
Additionally, we performed a control chemical reaction
without cells to monitor the kinetics of the reaction. To
determine the role of plasminogen binding to HDMVEC,
these assays were also performed including 6-aminocaproic
acid (6-ACA, Sigma Chemical Co., Cat #A2504; 1 mM) in
the final reaction mixture as antagonist of this binding.
In vitro Angiogenesis Assay
200 µL of HDMVECs cell suspension (5 × 104 cells/ml from
passage 4) in EGM-2MV medium were seeded on 50 µL of
polymerized (37°C for 30 min) Matrigel® (BD Biosciences, Cat
#354234) in a 96 well plate. After 18 h incubation (37°C and 5%
CO2), Fluorophore/calcein AM (Molecular Probes, Inc. Cat
#C1430) was added to stain cells. Image acquisition of tubular
network was achieved by fluorescence microscopy (Nikon Eclipse
e800 microscope coupled with an automated imager Nikon ACT-
1, Nikon Instruments Inc. Melville, NY) and Sigma Scan Pro
software (SPSS, Chicago, IL) was used to determine tube surface
area (Perez-Aso et al., 2014; Vicente et al., 2016).
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Statistical Analysis
Differences between groups in the in vitro studies were analyzed
by means of one-way analysis of variance (ANOVA) by Dunnet’s
multiple comparison test performed by GraphPad Prism 4
software (GraphPad Software, Inc. San Diego, CA).
RESULTS
An Adenosine A2A Receptor Agonist
Diminishes PAI-1 Production Without
Modifying tPA anduPAProduction inHuman
Dermal Microvascular Endothelial Cells
The expression of the key components of the plasminogen
activation system, uPA and its receptor (uPAR), as well as its
inhibitor PAI-1, is induced early during re-epithelialization in the
migrating epithelial sheet in incisional wounds in mice (Sulniute
et al., 2016). In contrast, the vascular endothelium is considered
to be the major site of synthesis and release of tPA (Emeis et al.,
1997). Since we have previously shown that adenosine A2A
receptor activation promoted wound revascularization by
promoting both angiogenesis and vasculogenesis (Montesinos
and Valls, 2010), we investigated its effect on human dermal
microvascular endothelial cells (HDMVEC).
HDMVEC secreted both types of plasminogen activators,
tPA and uPA, in lesser amounts than their inhibitor PAI-1
(Figures 1A–C). The addition of increasing amounts of the
selective A2A receptor agonist did not produce any appreciable
change in the secretion of tPA and uPA, but significantly
diminished the levels of PAI-1 present in the conditioned
media of HDMVEC (79.3 ± 12.1 ng/ml in 10−6 M CGS-21680
treated vs. 171.2 ± 9.3 ng/ml in untreated HDVECs, ***p < 0.001,
n  4, Figure 1C). Real time RT-PCR determination of themRNA
levels for tPA, uPA and PAI-1 showed that A2A adenosine
receptor activation did not affect tPA and uPA mRNA
expression in HDMVECs while decreasing PAI-1 message
levels (39% reduction from control by 10–6 M CGS-21680, p 
0.050, n  3, Figures 1D–F). Therefore, the effect of adenosine
A2A receptor activation on the level of uPA, tPA and PAI-1
expression correlated with the effect on released proteins to the
condition media.
Adenosine A2A Receptor Activation
Increases Annexin A2 Expression in
HDMVEC
Since we had observed that CGS-21680 treatment did not affect
the expression and the release of tPA by HDMVEC, we decided to
investigate the production of annexin A2, a protein that acts as an
endothelial cell membrane co-receptor of plasminogen and tPA
(Hajjar et al., 1994). Annexin A2 is an abundant protein (∼36 KD)
in HDMVECs with mainly perinuclear localization. The
activation of A2A adenosine receptors by CGS-21680
significantly increased the overall levels of this protein, shifting
its localization toward the cellular membrane (Figures 2A,C).
These findings were further confirmed by confocal laser scanning
microscopy (Figure 2D).
In order to determine whether there is any physical interaction
between endogenous tPA and annexin A2, we
FIGURE 1 | uPA, tPA and PAI-1 production by microvascular endothelial cells: HDMVEC (80–90% confluence) were incubated in the absence (control, vehicle
treated) or presence of the selective adenosine A2A receptor CGS-21680 for 24 h for protein detection or 4 h for mRNA expression. Supernatants were collected and
frozen at −80°C until used and cells were lyzed in Trizol solution for total RNA extraction. Total tPA (A), uPA (B), and PAI-1 (C) content in supernatants were determined
by ELISA. Results were normalized to 105 cells. Data are presented as the mean ± SEM of four experiments in triplicate (n  4). mRNA expression of tPA (D), uPA
(E), and PAI-1 (F) were assessed by real-time PCR and normalized to GAPDH as described. Results are expressed as mean of percentage of control ± SEM, of 3
experiments in duplicates (n  3). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control, ANOVA followed by Dunnet’s postest.
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FIGURE 2 | Annexin A2 production by microvascular endothelial cells: HDMVEC (80–90% confluence) were incubated in the absence (control, vehicle treated) or
presence of the selective A2A adenosine receptor CGS-21680 (10
−6 M) for 24 h. (A)Whole cell lysates (5 μg/lane) were separated by 10% SDS-PAGE and annexin A2
and ß-actin were detected by immunoblotting. Protein expression was measured by optical densitometry of the bands and results were expressed as % integrated
optical density (IOD) respect control and normalized to ß-actin and are presented as the mean ± SEM (n  16). **p < 0.01 vs. control, t de Dunnet. (B) Co-
immunoprecipitation of tPA and Annexin A2. Precleared cell lysates were immunoprecipitated with a monoclonal antibody against annexin A2, resuspended in sample
loading buffer and tPA was detected by immunoblotting. Shown is a representative experiment of four. WL: Whole lysate; IP: immunoprecipitates. (C) ethanol fixed cells
(Continued )
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immunoprecipitated annexin A2 and observed that the amount
of tPA (∼60 KD) that co-precipitated with annexin A2 increased
markedly in the CGS21680-treated cells (Figure 2B).
Increased Annexin A2 Production
Contributes to Cell Associated-tPA Plasmin
Generation by Adenosine A2A Receptor
Stimulated HDMVEC
We determined the functionality of the increased annexin A2
production by an indirect test of plasminogen activation, through
the degradation of a specific substrate for the newly generated
plasmin. As a control, we performed the assay in the absence of
cells and confirmed the selectivity of the substrate, which was
only degraded after activation of plasminogen by recombinant
tPA (Figure 3A). We observed that the low amounts of
plasminogen activators, tPA and uPA, endogenously produced
by both untreated and adenosine A2A agonist treated HDMVEC
were not sufficient to activate plasminogen to plasmin
(Figure 3B). To detect exclusively membrane-bound tPA-
associated plasminogen activation it was necessary to incubate
exogenous recombinant tPA for 30 min and then washed away
before the addition of substrate and Glu-plasminogen. The lag
time observed in plasmin generation by HDMVEC-surface
bound tPA, about 20–30 min, is similar to that described for
cerebral microvascular endothelial cells (Semov et al., 2005), but
much longer than for pancreatic or breast cancer cells (Diaz et al.,
2004; Sharma et al., 2010).
CGS-21680 pre-treatment produced an increase in membrane
bound tPA-associated plasmin generation by HDMVEC (Figures
3B,C). Both preincubation with a specific antibody against
annexin A2 (4 μg/ml) before binding of recombinant tPA, or
the presence of the plasmin inhibitor 6-ACA (1 mM) in the final
reaction, markedly inhibited plasmin generation and completely
abolished the CGS-21680-mediated increase in cell associated-
plasmin generation (Figure 3C).
Plasmin and Annexin A2 Participates in the
Proangiogenic Effect of an Adenosine A2A
Receptor Agonist
Once we established that adenosine A2A receptor activation
increased annexin A2 expression resulting in an increase in
cell-bound tPA and thereby accelerated plasminogen
activation, we evaluated the contribution of this system in
another functional assay, the endothelial cell formation of a
tubular network on a three-dimensional matrix. In a previous
study, we demonstrated that A2A receptor activation stimulates
endothelial network formation in Matrigel and established the
concentration dependent effect for the agonist CGS-21680 in this
model (Desai et al., 2005). For the present study we selected the
concentration of 1 μM, which had shown a maximal effect that
could be abrogated by a selective A2A antagonist (Desai et al.,
2005). HDMVEC network formation was significantly inhibited
by the plasmin inhibitor 6-ACA (1 mM) and a murine
monoclonal antibody against annexin A2, but not a control
murine antibody (Figure 4). In contrast, antibodies against
tPA, uPA and PAI-1 did not affect basal network formation.
Interestingly, adenosine A2A receptor-mediated increases in
network formation were blocked by 6-ACA and antibodies
against PAI-1 and tPA but not uPA or annexin A2 (Figure 4).
DISCUSSION
We report here evidence for a novel mechanism by which
adenosine receptors promote angiogenesis: stimulation of
adenosine A2A receptors promotes the expression of annexin
A2 on the surface of endothelial cells, which binds tPA to the
surface of the cells, providing for localized activation of
plasminogen to plasmin. Moreover, adenosine A2A receptor
stimulation diminishes endothelial PAI-1 production as well.
In the absence of tPA, adenosine receptor activation does not
promote wound healing (Montesinos et al., 2015) and, when this
mechanism is interrupted, adenosine A2A receptor activation
does not stimulate angiogenesis in vitro.
Endothelial cells derived from dermal microvasculature secreted
small quantities of tPA into the culture medium, results which
contrast with a prior report that human umbilical vein endothelial
cells release much larger quantities of tPA (Speiser et al., 1987).
Agents that increase intracellular cAMP levels (prostacyclin,
isoproterenol, forskolin, cholera toxin) and cAMP analogs induce
a dose and time-dependent acute release of tPA andVonWillebrand
factor from HUVEC (Hegeman et al., 1998). Since signaling of
adenosine A2A receptor is supposed to occur through the activation
of adenylate cyclase (Fredholm et al., 2011), we expected that
selective doses of CGS21680 would induce tPA release from
HDMVEC as well. However, we did not observe any appreciable
change in tPA release, in agreement with an earlier report
showing that cAMP analogs did not modify tPA secretion in
non-stimulated HUVEC but potentiated the phorbol ester-
induced secretion of tPA, and inhibited both basal and
phorbol ester-increased PAI-1 secretion in HUVEC (Levin
et al., 1989). Similarly, in this study we observed that
adenosine A2A receptor activation decreased the high levels
of secreted PAI-1 in microvascular endothelial cells by
FIGURE 2 | were immunostained with amonoclonal antibody against annexin A2 and a secondary antibody Alexa Fluor 488-conjugated goat antimouse, counterstained
with Hoechst 33342 and visualized by fluorescence microscopy (original magnification ×400). Average fluorescence intensity of annexin A2 immunostained HDMVEC
was determined with MetaMorph
®
software. Results are expressed in intensity arbitrary units for 30 cells per condition and presented as the mean ± SEM of 5
experiments in triplicate (n  5). *p < 0.05 vs. control, ANOVA followed by Dunnet’s postest. Negative: negative control without primary antibody. (D) A z-series of images
were acquired at 2 µm steps by confocal laser scanning microscopy of ethanol fixed cells immunostained with a monoclonal antibody against annexin A2 and a
secondary antibody Alexa Fluor 488-conjugated goat antimouse and counterstained with Hoechst 33342. The resulting images were overlaid and analyzed using the
Leica software, v2.61. Results are expressed in intensity arbitrary units per condition and presented as the mean ± STDV (n  2).
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decreasing both message expression and its subsequent release.
This effect could be of clinical relevance, since high plasma
levels of PAI-1 have been associated with vascular dysfunction
and increased cardiovascular risks in several chronic
pathological disorders such as hypertension, diabetes and
metabolic syndrome (Naya et al., 2007; Lijnen, 2009; Sillen
and Declerck, 2020).
The calcium-dependent phospholipid-binding protein
annexin A2 is a proposed endothelial cell membrane co-
receptor for plasminogen that can stimulate tPA–mediated
plasminogen activation in the complete absence of fibrin
(Hajjar et al., 1994) and plays an important role in
angiogenesis by localizing plasmin activity on the endothelial
cell surface (Ling et al., 2004). We then tried to explore a new
hypothesis, that tPA could be indirectly involved in the
promotion of wound revascularization by adenosine A2A
receptor activation through annexin A2. Selective doses of
CGS21680 markedly augmented annexin A2 production by
HDMVEC, which interacted with endogenously generated
tPA. However, our results do not exclude the possibility that
this interaction happened post-extraction, and it is not clear if the
localization of annexin A2 is in the inner or outer leaflet of the
plasma membrane of endothelial cells when its translocation was
promoted by ionophore A23187 treatment.
Recently, controversy has emerged concerning the role of
annexin A2 in binding plasminogen (Brodsky et al., 2001).
The involvement of annexin A2 in the proteolytic activity of
cell-bound tPA was confirmed since antibodies against the
C-terminus of annexin A2 markedly reduced plasmin
generation, although did not inhibited it completely, probably
by blocking plasminogen binding to the lysine 307 at the
C-terminus of annexin A2 (Liu and Hajjar, 2016). Similarly,
the plasmin inhibitor 6-ACA which acts by blocking the
plasminogen and plasmin binding site to lysine residues in
either fibrin or the cell surface (Hatziapostolou et al., 2003),
markedly inhibited cell-bound tPA-induced plasmin generation,
although certain residual plasmin activity was still detectable,
suggesting that in the cell microenvironment there are other
proteases that could activate unbound plasminogen, since, as we
observed in the absence of cells, the substrate is not degradable by
inactive plasminogen.
The contribution of the different components of the
plasminogen/plasmin system to the angiogenic process has been
previously determined (Brodsky et al., 2001; Kruithof and
Dunoyer-Geindre, 2014). The Matrigel® in vitro assay had
previously been used to study the proangiogenic effect of
adenosine A2A agonists (Desai et al., 2005) and the involvement
of plasmin in the endothelial cell tubular network formation
(Semov et al., 2005). Given that often incomplete lumen
formation occurs (Stefansson et al., 2003), determination of
total area constitutes a standardized method that facilitates
comparisons among different conditions. Our results confirm
that plasmin contributes to the angiogenic process, since the
plasmin inhibitor 6-ACA suppressed endothelial cell tubular
network formation, in a similar way as previously shown for
cerebral microvascular endothelial cells (Semov et al., 2005). In
contrast, antibodies against either uPA or tPA produced a small
non-significant reduction in tube formation. Nevertheless, the anti-
tPA antibody and the plasmin inhibitor prevented the stimulatory
effect of the adenosine A2A receptor agonist (characterized by
FIGURE 3 | Plasminogen activation by microvascular endothelial cells: (A)
Chemical control reaction reagentswere added towellswith no cells. Fluorescence
was detected at 360-nm excitation/460-nm emission setting over time. Subs:
fluorogenic substrate (50 mM), PLG: Glu-plasminogen (100 nM), rtPA:
recombinant tPA (10 nM). (B) HDMVEC (80–90% confluence) were incubated in
the absence (control, vehicle treated) or presence of the selective A2A adenosine
receptor CGS-21680 (10−6 M) for 24 h. Time-course plasmin generation by cell
bound-tPA was determined in cells after washing twice with PBS and incubation
with 10 nM rtPA for 20 min. After two PBS washes, Glu-plasminogen (100 nM)
and the substrate (50 µM) were added and fluorescence was detected. C: control
vehicle-treated cells; CGS: 10−6 M CGS-21680-treated cells. (C) In other set of
experiments for plasmin generation by cell bound-tPA after 6 h, monoclonal
antibody anti-annexinA2 (4 μg/ml) was added10 min prior the addition of rtPAand
6-ACA (1 mM)was incubated for 10 min prior addition of theGlu-plasminogen and
the substrate. Results are expressed as mean relative fluorescence units (rfu) +
SEM (n  6 in quadruplicate). **p < 0.01, ***p < 0.001 vs. control cells, ANOVA
followed by Dunnet’s postest.
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FIGURE 4 | Microvascular endothelial cell network formation in vitro: HDMVEC (104 cells, passage 4) were seeded in 200 µL of EGM-2MV onto 50 µL of
polymerized Matrigel in 96 well plates. Cells were treated with either vehicle or CGS-216080 (10−6 M) in absence or presence of either the plasmin inhibitor 6-ACA
(1 mM), blocking antibodies against annexin A2 (4 μg/ml), PAI-1, tPA or uPA (20 μg/ml) or their corresponding control mouse or goat IgG (20 μg/ml). For fluorescence
detection of tubular network (A), fluorophore/calcein AM (5 μM) was added after 18h incubation and image acquisition of tube formation was achieved by
fluorescence microscopy (original magnification ×40). Total area of the cellular networks (B) was determined with SigmaScan Pro software and expressed as arbitrary
area units (AAU). Results are presented asmean ±SEM (n  3 or 4 in triplicate) *p < 0.05, **p < 0.01 vs. control;^p < 0.05 vs. anti-annexin A2 control; +p< 0.05 vs. anti-uPA
control, ANOVA followed by Dunnett’s postest.
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formation of larger tubules), whereas the anti-uPA antibody had no
effect, suggesting that plasminogen activation to plasmin by tPA
participates in the proangiogenic effect of adenosine. Similarly, an
antibody against PAI-1 did not blockHDMVEC tubular formation
on Matrigel, but prevented the stimulatory effect of CGS-21680.
The role of PAI-1 in angiogenesis is controversial, while some
authors have described PAI-1 as a limiting factor of in vitro
angiogenesis assays (Stefansson et al., 2003), others have shown
that PAI-1 expression is increased during tissue repair and
remodeling to maintain the integrity of the fibrin matrix
necessary for proper cellular migration (Isogai et al., 2001),
probably through its interactionwith vitronectin (Basu et al., 2009).
Tube formation by HDMVEC was greatly hindered by a
neutralizing antibody against the C-terminus of annexin A2,
which was modestly reversed by adenosine A2A receptor
activation, suggesting that the role of this protein in
angiogenesis is not only due to its interaction with tPA.
Annexin A2 belongs to the annexin family of proteins, which
can bind membranes via negatively charged phospholipids and
Ca2+ ions (Monastyrskaya et al., 2007). This could allow them to
organize the interface between the cytoplasm and the cytoplasmic
face of cellular membranes (Rescher and Gerke, 2004). The
N-terminus of annexin A2 binds p11/S100A10 leading to the
formation of a heterotetramer, resulting in a several fold
increase in the Ca2+ sensitivity of membrane aggregation
(Zibouche et al., 2008; Madureira et al., 2012). In addition,
active cathepsin B, bound to the subunit p11/S100A10 of the
annexin A2 heterotetramer (AIIt), partially localized to caveolae
of human umbilical vein endothelial cells (HUVEC) in
extracellular matrix degradation during tube formation
(Cavallo-Medved et al., 2009). Blockade of annexin A2 function
in vivo, by gene ablation or by a diet leading to hyper-
homocysteinemia, leads to loss of endothelial cell surface
plasmin generation, reducing endothelial cell migratory capacity
that leads to angiogenic failure (Flood and Hajjar, 2011). Our
results corroborate the more prominent role for Annexin A2 in
plasminogen activation involved in angiogenesis, indistinctly of the
heterotetramer formation with p11/S100A10, since blockade of the
C-terminus markedly compromises both branching and tube
length in the Matrigel® assay. However, we cannot rule out the
potentiating role of the two S100A10 molecules, which facing away
from the membrane, create a platform for interaction with tPA in
the extracellular space (Weisz and Uversky, 2020).
The results presented here corroborate the proangiogenic
effect of adenosine A2A receptor activation suggesting an
indirect contribution of the tissue plasminogen activator
through diminished release of its main inhibitor PAI-1
and increased expression of its cell surface receptor
annexin A2.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article
will be made available by the authors, without undue
reservation.
AUTHOR CONTRIBUTIONS
MM, MT and BC contributed to conception and design of the
study. MV, MS, AW, MN and MM performed the experiments
and data analysis. JA andMP-A performed the statistical analysis.
MM and MV wrote the first draft of the manuscript. MN, MT, JA
and MP-A wrote sections of the manuscript. All authors
contributed to manuscript revision, read, and approved the
submitted version.
FUNDING
This work was supported by grants to BC from the National
Institutes of Health (AR54897, AR56672), the NYU-HHC
Clinical and Translational Science Institute (UL1 TR000038),
OSI Pharmaceuticals and the Vilcek Foundation and Grants to
MM from the Instituto de Salud Carlos III of Spain-FEDER (FIS
05/1659), the Valencian Government (Conselleria d’Empresa,
Universitat i Ciència, GV05/031), the Spanish Ministry of
Science and Innovation-FEDER (SAF 2009-10347, SAF 2017-
85806-R and RETICEF RD06/0013/2001) and the University of
Valencia (UV-AE-09-5810). MV was beneficiary of a
predoctoral fellowship from the Instituto de Salud Carlos III
of Spain.
ACKNOWLEDGMENTS
We are grateful to the SCSIE (Servicio Central de Soporte a la
Investigación Experimental) of the University of València, for
technical assistance.
REFERENCES
Basu, A., Menicucci, G., Maestas, J., Das, A., and McGuire, P. (2009). Plasminogen
activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of
oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 50, 4974–4981.
doi:10.1167/iovs.09-3619
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., and Varani, K. (2018).
Pharmacology of adenosine receptors: the state of the art. Physiol. Rev. 98,
1591–1625. doi:10.1152/physrev.00049.2017
Brodsky, S., Chen, J., Lee, A., Akassoglou, K., Norman, J., and Goligorsky, M. S.
(2001). Plasmin-dependent and -independent effects of plasminogen activators
and inhibitor-1 on ex vivo angiogenesis. Am. J. Physiol.-Heart Circul. Physiol.
281, H1784–H1792. doi:10.1152/ajpheart.2001.281.4.h1784
Cavallo-Medved, D., Rudy, D., Blum, G., Bogyo, M., Caglic, D., and Sloane, B. F.
(2009). Live-cell imaging demonstrates extracellular matrix degradation in
association with active cathepsin B in caveolae of endothelial cells during
tube formation. Exp. Cel Res. 315, 1234–1246. doi:10.1016/j.yexcr.2009.
01.021
Che, J., Chan, E. S. L., and Cronstein, B. N. (2007). Adenosine A2A receptor
occupancy stimulates collagen expression by hepatic stellate cells via pathways
involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2
signaling cascade or p38 mitogen-activated protein kinase signaling pathway.
Mol. Pharmacol. 72, 1626–1636. doi:10.1124/mol.107.038760
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 6541049
Valls et al. Adenosine and the Fibrinolytic System in Angiogenesis
Colangelo, M. T., Galli, C., and Guizzardi, S. (2020). The effects of
polydeoxyribonucleotide on wound healing and tissue regeneration: a
systematic review of the literature. Regenerative Med. 15, 1801. doi:10.2217/
rme-2019-0118
Desai, A., Victor-Vega, C., Gadangi, S., Montesinos, M. C., Chu, C. C., and
Cronstein, B. N. (2005). Adenosine A2A receptor stimulation increases
angiogenesis by down-regulating production of the antiangiogenic matrix
protein thrombospondin 1. Mol. Pharmacol. 67, 1406–1413. doi:10.1124/
mol.104.007807
Diaz, V. M., Hurtado, M., Thomson, T. M., Reventos, J., and Paciucci, R. (2004).
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II
on the membrane of pancreatic cancer cells activates plasminogen and
promotes invasion in vitro. Gut 53, 993–1000. doi:10.1136/gut.2003.026831
Emeis, J. J., Eijnden-Schrauwen, Y. v. d., Hoogen, C. M. v. d., Priester, W. d.,
Westmuckett, A., and Lupu, F. (1997). An endothelial storage granule for
tissue-type plasminogen activator. J. Cel Biol. 139, 245–256. doi:10.1083/jcb.
139.1.245
Flood, E. C., and Hajjar, K. A. (2011). The annexin A2 system and vascular
homeostasis. Vasc. Pharmacol. 54, 59–67. doi:10.1016/j.vph.2011.03.003
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., and Müller, C. E.
(2011). International union of basic and clinical Pharmacology. LXXXI.
Nomenclature and classification of adenosine receptors-an update.
Pharmacol. Rev. 63, 1–34. doi:10.1124/pr.110.003285
Hajjar, K. A., Jacovina, A. T., and Chacko, J. (1994). An endothelial cell receptor for
plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol.
Chem. 269, 21191–21197. doi:10.1016/s0021-9258(17)31947-6
Hatziapostolou, M., Katsoris, P., and Papadimitriou, E. (2003). Different inhibitors
of plasmin differentially affect angiostatin production and angiogenesis. Eur.
J. Pharmacol. 460, 1–8. doi:10.1016/s0014-2999(02)02868-6
Hegeman, R. J., Eijnden-Schrauwen, v. d., and Emeis, J. J. (1998). Adenosine 3′:5′-
cyclic monophosphate induces regulated secretion of tissue-type plasminogen
activator and von Willebrand factor from cultured human endothelial cells.
Thromb. Haemost. 79, 853–858. doi:10.1055/s-0037-1615077
Isogai, C., Laug, W. E., Shimada, H., Declerck, P. J., Stins, M. F., Durden, D. L.,
et al. (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by
stimulating endothelial cell migration toward fibronectin. Cancer Res. 61,
5587–5594. doi:10.1007/978-1-4615-3358-0_11
Kruithof, E. K. O., and Dunoyer-Geindre, S. (2014). Human tissue-type
plasminogen activator. Thromb. Haemost. 112, 243–254. doi:10.1160/th13-
06-0517
Levin, E. G., Marotti, K. R., and Santell, L. (1989). Protein kinase C and the
stimulation of tissue plasminogen activator release from human endothelial
cells. J. Biol. Chem. 264, 16030–16036. doi:10.1016/s0021-9258(18)71583-4
Lijnen, H. R. (2009). Role of fibrinolysis in obesity and thrombosis. Thromb. Res.
123 (Suppl. 4), S46–S49. doi:10.1016/s0049-3848(09)70143-4
Ling, Q., Jacovina, A. T., Deora, A., Febbraio, M., Simantov, R., Silverstein, R. L.,
et al. (2004). Annexin II regulates fibrin homeostasis and neoangiogenesis in
vivo. J. Clin. Invest. 113, 38–48. doi:10.1172/jci19684
Liu, W., and Hajjar, K. A. (2016). The annexin A2 system and angiogenesis. Biol.
Chem. 397, 1005–1016. doi:10.1515/hsz-2016-0166
Madureira, P. A., O’Connell, P. A., Surette, A. P., Miller, V. A., andWaisman, D. M.
(2012). The biochemistry and regulation of S100A10: a multifunctional
plasminogen receptor involved in oncogenesis. J. Biomed. Biotechnol. 2012,
353687. doi:10.1155/2012/353687
Mirsaeidi, M., Gidfar, S., Vu, A., and Schraufnagel, D. (2016). Annexins family:
insights into their functions and potential role in pathogenesis of sarcoidosis.
J. Transl Med. 14, 89. doi:10.1186/s12967-016-0843-7
Monastyrskaya, K., Babiychuk, E. B., Hostettler, A., Rescher, U., and Draeger, A.
(2007). Annexins as intracellular calcium sensors. Cell Calcium 41, 207–219.
doi:10.1016/j.ceca.2006.06.008
Montesinos, M. C., Desai, A., Chen, J.-F., Yee, H., Schwarzschild, M. A., Fink, J. S.,
et al. (2002). Adenosine promotes wound healing and mediates angiogenesis in
response to tissue injury via occupancy of A2A receptors. Am. J. Pathol. 160,
2009–2018. doi:10.1016/s0002-9440(10)61151-0
Montesinos, M. C., Desai-Merchant, A., and Cronstein, B. N. (2015). Promotion of
wound healing by an agonist of adenosine A2A receptor is dependent on tissue
plasminogen activator. Inflammation 38, 2036–2041. doi:10.1007/s10753-015-
0184-3
Montesinos, M. C., Shaw, J. P., Yee, H., Shamamian, P., and Cronstein, B. N.
(2004). Adenosine A2A receptor activation promotes wound
neovascularization by stimulating angiogenesis and vasculogenesis. Am.
J. Pathol. 164, 1887–1892. doi:10.1016/s0002-9440(10)63749-2
Montesinos, M. C., and Valls, M. D. (2010). “Stimulation of wound
revascularization by adenosine receptor activation,” in Extracellular ATP
and adenosine as regulators of endothelial cell function. Editors
E. Gerasimovskaya and E. Kaczmarek (Dordrecht, Springer), 95–112.
Naya, M., Tsukamoto, T., Inubushi, M., Morita, K., Katoh, C., Furumoto, T., et al.
(2007). Elevated plasma plasminogen activator inhibitor type-1 is an
independent predictor of coronary microvascular dysfunction in
hypertension. Circ. J. 71, 348–353. doi:10.1253/circj.71.348
Perez-Aso, M., Flacco, N., Carpena, N., Montesinos, M. C., D’Ocon, P., and Ivorra,
M. D. (2014). β-Adrenoceptors differentially regulate vascular tone and
angiogenesis of rat aorta via ERK1/2 and p38. Vasc. Pharmacol. 61, 80–89.
doi:10.1016/j.vph.2014.04.003
Plekhanova, O., Parfyonova, Y., Beloglazova, I., Berk, B. C., and Tkachuk, V.
(2019). Oligonucleotide microarrays identified potential regulatory genes
related to early outward arterial remodeling induced by tissue
plasminogen activator. Front. Physiol. 10, 493. doi:10.3389/fphys.2019.
00493
Rescher, U., and Gerke, V. (2004). Annexins—unique membrane binding proteins
with diverse functions. J. Cel Sci. 117, 2631–2639. doi:10.1242/jcs.01245
Rubina, K. A., Sysoeva, V. Y., Zagorujko, E. I., Tsokolaeva, Z. I., Kurdina, M. I.,
Parfyonova, Y. V., et al. (2017). Increased expression of uPA, uPAR, and PAI-1
in psoriatic skin and in basal cell carcinomas. Arch. Dermatol. Res. 309,
433–442. doi:10.1007/s00403-017-1738-z
Semov, A., Moreno, M. J., Onichtchenko, A., Abulrob, A., Ball, M., Ekiel, I., et al.
(2005). Metastasis-associated protein S100A4 induces angiogenesis
through interaction with Annexin II and accelerated plasmin
formation. J. Biol. Chem. 280, 20833–20841. doi:10.1074/jbc.
m412653200
Shaikh, G., and Cronstein, B. (2016). Signaling pathways involving adenosine A2A
and A2B receptors in wound healing and fibrosis. Purinergic Signal. 12,
191–197. doi:10.1007/s11302-016-9498-3
Sharma, M., Ownbey, R. T., and Sharma, M. C. (2010). Breast cancer cell surface
annexin II induces cell migration and neoangiogenesis via tPA dependent
plasmin generation. Exp. Mol. Pathol. 88, 278–286. doi:10.1016/j.yexmp.2010.
01.001
Sillen, M., and Declerck, P. J. (2020). Targeting PAI-1 in cardiovascular disease:
structural insights into PAI-1 functionality and inhibition. Front. Cardiovasc.
Med. 7, 622473. doi:10.3389/fcvm.2020.622473
Simone, T. M., Longmate, W. M., Law, B. K., and Higgins, P. J. (2015). Targeted
inhibition of PAI-1 activity impairs epithelial migration and wound closure
following cutaneous injury. Adv. Wound Care 4, 321–328. doi:10.1089/wound.
2014.0611
Speiser, W., Anders, E., Preissner, K., Wagner, O., and Muller-Berghaus, G. (1987).
Differences in coagulant and fibrinolytic activities of cultured human
endothelial cells derived from omental tissue microvessels and umbilical
veins. Blood 69, 964–967. doi:10.1182/blood.v69.3.964.964
Stefansson, S., McMahon, G., Petitclerc, E., and Lawrence, D. (2003). Plasminogen
activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Cpd 9, 1545–1564. doi:10.2174/1381612033454621
Sulniute, R., Shen, Y., Guo, Y.-Z., Fallah, M., Ahlskog, N., Ny, L., et al. (2016).
Plasminogen is a critical regulator of cutaneous wound healing. Thromb.
Haemost. 115, 1001–1009. doi:10.1160/th15-08-0653
Troncoso, F., Herlitz, K., Acurio, J., Aguayo, C., Guevara, K., Castro, F. O., et al.
(2020). Advantages in wound healing process in female mice require
upregulation a2a-mediated angiogenesis under the stimulation of 17β-
estradiol. Ijms 21, 7145. doi:10.3390/ijms21197145
Valls, M. D., Cronstein, B. N., and Montesinos, M. C. (2009). Adenosine receptor
agonists for promotion of dermal wound healing. Biochem. Pharmacol. 77,
1117–1124. doi:10.1016/j.bcp.2008.11.002
Vicente, D., Hernández, B., Segura, V., Pascual, D., Fornaciari, G., Monto, F., et al.
(2016). Methodological approach to use fresh and cryopreserved vessels
as tools to analyze pharmacological modulation of the angiogenic
growth. J. Cardiovasc. Pharmacol. 68, 230–240. doi:10.1097/fjc.
0000000000000407
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 65410410
Valls et al. Adenosine and the Fibrinolytic System in Angiogenesis
Weisz, J., and Uversky, V. N. (2020). Zooming into the dark side of human
annexin-S100 complexes: dynamic alliance of flexible partners. Int. J. Mol. Sci.
21. doi:10.3390/ijms21165879
Zibouche, M., Vincent, M., Illien, F., Gallay, J., and Ayala-Sanmartin, J. (2008). The
N-terminal domain of annexin 2 serves as a secondary binding site during
membrane bridging. J. Biol. Chem. 283, 22121–22127. doi:10.1074/jbc.m801000200
Conflict of Interest: BC holds or has filed applications for patents on the use of
adenosine A2A receptor agonists to promote wound healing and use of A2A
receptor antagonists to inhibit fibrosis; use of adenosine A1 receptor antagonists to
treat osteoporosis and other diseases of bone; the use of adenosine A1 and A2B
Receptor antagonists to treat fatty liver; and the use of adenosine A2A receptor
agonists to prevent prosthesis loosening. He is consultant (within the past two
years) for King Pharmaceuticals (licensee of patents on wound healing and fibrosis
above), CanFite Biopharmaceuticals, Savient Pharmaceuticals, Bristol-Myers
Squibb, Roche Pharmaceuticals, Cellzome, Tap (Takeda) Pharmaceuticals,
Prometheus Laboratories, Regeneron (Westat, DSMB), Sepracor, Amgen,
Endocyte, Protalex, Allos, Inc. Combinatorx, Kyowa Hakka, received honoraria
from Tap (Takeda) Pharmaceuticals and holds stock in CanFite
Biopharmaceuticals received for membership in Scientific Advisory Board.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2021 Valls, Soldado, Arasa, Perez-Aso, Williams, Cronstein, Noguera,
Terencio and Montesinos. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 65410411
Valls et al. Adenosine and the Fibrinolytic System in Angiogenesis
